Payment overview · 2025
General Payments
$229.34
11 reported records · 8 companies
Healthcare provider profile · identity verified
Brayden Mcbride, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGVILLE, UT · NPI 1831363225
Verified facts
What the public records show
CMS Open Payments records show Brayden Mcbride, M.D. received $229.34 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.87 | 32.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.75 | 13.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.91 | 13.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.41 | 10.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.69 | 8.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.10 | 7.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.48 | 7.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.13 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.34 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.87 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.35 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $31.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 342 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 91 |
| Omeprazole | Omeprazole | 239 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 217 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 53 |
| Valsartan | Valsartan | 161 | 48 |
| Simvastatin | Simvastatin | 156 | 45 |
| Gabapentin | Gabapentin | 155 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 45 |
| Lisinopril | Lisinopril | 130 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 125 | 37 |
| Celecoxib | Celecoxib | 124 | 56 |
| Losartan Potassium | Losartan Potassium | 117 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 28 |
| Metformin Hcl | Metformin Hcl | 97 | 32 |
| Metformin Hcl Er | Metformin Hcl | 97 | 36 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 95 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 33 |
| Furosemide | Furosemide | 90 | 31 |
| Potassium Chloride | Potassium Chloride | 84 | 26 |
| Trazodone Hcl | Trazodone Hcl | 84 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 81 | 22 |
| Lorazepam | Lorazepam | 79 | 14 |
| Pregabalin | Pregabalin | 77 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 19 |
| Eliquis | Apixaban | 72 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 24 |
| Donepezil Hcl | Donepezil Hcl | 70 | 18 |
| Alprazolam | Alprazolam | 69 | 13 |
| Clonazepam | Clonazepam | 65 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 20 |
| Prednisone | Prednisone | 63 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 18 |
| Tramadol Hcl | Tramadol Hcl | 60 | 25 |
| Mounjaro | Tirzepatide | 58 | 14 |
| Montelukast Sodium | Montelukast Sodium | 56 | 16 |
| Allopurinol | Allopurinol | 55 | 18 |
| Ozempic | Semaglutide | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 15 |
| Cefdinir | Cefdinir | 45 | 32 |
| Estradiol | Estradiol | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 18 |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 15 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Finasteride | Finasteride | 36 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 33 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 14 |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 29 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 21 |
| Bupropion Xl | Bupropion Hcl | 31 | 15 |
| Fluconazole | Fluconazole | 31 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | 18 |
| Progesterone | Progesterone, Micronized | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 17 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Ofloxacin | Ofloxacin | 21 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 19 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.34 · 11 records | ABBVIE INC. | Dexcom G6 Transmitter, JARDIANCE, MINIMED 780G, NURTEC ODT, Ozempic, QULIPTA, Qelbree, Rybelsus, Sunosi, UBRELVY, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error